Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bevacizumab
Find trials that include:  Any drugs shown
Results 1-25 of 87 for your search:
Start Over
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: IRB# 55264, NCI-2012-01118, HCI55264, NCT01580969
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-055, NCI-2015-01704, NCT02521051
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
Hydroxychloroquine, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 070806, NCI-2012-00527, CINJ-070806, NCT01006369
Pegylated Liposomal Doxorubicin Hydrochloride and Bevacizumab in Treating Patients with Advanced Kaposi Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0130, NCI-2013-01450, 090130, NCT00902239, P09493, NCT00923936
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: AVF4535s, NCI-2010-01315, NCT01149850
Radiation Therapy, Bevacizumab, Erlotinib Hydrochloride, or Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: 10-321, NCI-2011-03059, DFCI 10-321, NCT01182350
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CERN09-02, NCI-2011-01283, NCT01295944
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Start Over